Daily Tax Report: State provides authoritative coverage of state and local tax developments across the 50 U.S. states and the District of Columbia, tracking legislative and regulatory updates,...
By Che Odom
Shareholders of Medtronic Inc. may proceed with claims related to taxes on capital gains incurred after the company completed its 2014 inverse merger with Covidien PLC, according to a ruling by Minnesota’s highest court.
The Minnesota Supreme Court ruled Aug. 16 that the shareholders may be able to show direct, rather than derivative, harm when it comes to capital gains tax claims, because the tax liability was imposed on them solely in their status as shareholders ( In re Medtronic, Inc. S’holder Litig. , 2017 BL 286515, Minn., A15-0858, 8/16/17 ).
The justices, however, affirmed a lower court’s dismissal of claims of injuries due to excise tax reimbursements granted Medtronic directors and officers. Those injuries, if any, are derivative, which means the harm caused to shareholders derived from harm sustained by the company, the court ruled.
Corporate reimbursement of an excise-tax liability resulting from the transaction “is at bottom an alleged waste of corporate assets,” the opinion said.
Medtronic bought Covidien, a public Irish company, by first establishing an Ireland-based company, Medtronic PLC, which then took over both Covidien and Minnesota-based Medtronic Inc. This inversion purchase created a taxable event for Medtronic under federal and state laws, the court said.
Its shareholders sued in Minnesota court, asserting federal and state claims.
Medtronic PLC, which has a market cap of about $115 billion, develops therapeutic and diagnostic medical products.
To contact the reporter on this story: Che Odom at COdom@bna.com
To contact the editor responsible for this story: Jennifer McLoughlin at firstname.lastname@example.org
Text of the ruling is http://src.bna.com/rLU.
Copyright © 2017 Tax Management Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)